Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Impact of chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma on sperm deoxyribonucleic acid integrity Cristian O'Flaherty, Ph.D., Barbara.

Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation? Micah.

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger? Matthew.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Michael M. Alper, M.D. Fertility and Sterility

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women Ioannis E. Messinis, M.D., Ph.D.,

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Do anti-mullerian hormone levels predict ovarian reserve in SLE patients presenting for hematopoietic stem cell transplant? H. Browne, A. Armstrong,

Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH) P. Barriere, T. Freour, D. Masson,

Robert F. Casper, M.D. Fertility and Sterility

Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study Ahmet Erdem, M.D., Mehmet Erdem,

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged.

Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized.

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Fertility and Sterility

GnRH antagonists may affect endometrial receptivity

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells Toshiaki Taketani, M.D., Yoshiaki.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Are endometrial parameters by three-dimensional ultrasound and power Doppler angiography related to in vitro fertilization/embryo transfer outcome? Luis.

Efficacy of luteinizing hormone activity in patients undergoing in vitro fertilization and treated only with low-dose recombinant choriogonadotropin alfa.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Fertility and Sterility: an evaluation

Paolo Moghetti, M.D. Fertility and Sterility

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins:

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.

Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis Ernesto Bosch, M.D., Elena.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Ahmed Badawy, M.D., Aboubakr.

The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.

In vitro sildenafil citrate use as a sperm motility stimulant

Bárbara Oriol, M. D. , Ana Barrio, M. D. , Alberto Pacheco, Ph. D

Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy Eman A. Elgindy,

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient’s body mass index and the number of larger follicles

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Presentation transcript:

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues, M.D., Ph.D., Emmanuelle Massé-Laroche, M.D., Jeanne Reboul-Marty, M.D., Oksana Boîko, M.D., Céline Meynant, M.D., Isabelle Cédrin-Durnerin, M.D. Fertility and Sterility Volume 96, Issue 3, Pages 600-604 (September 2011) DOI: 10.1016/j.fertnstert.2011.06.061 Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Serum LH (upper part) and P (lower part) values during controlled ovarian stimulation in patients treated with GnRH agonist and antagonist regimens. The figure illustrates means ± SEM. Asterisks indicate P<.001. Fertility and Sterility 2011 96, 600-604DOI: (10.1016/j.fertnstert.2011.06.061) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions